Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons (Q38107500)

29 August 2017

Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons (English)

1 reference

29 August 2017

0 references

1 reference

3

Adeeba Kamarulzaman

1 reference

29 August 2017

Graeme Meintjes

2

0 references

author name string

Shui Shan Lee

series ordinal

1

1 reference

PubMed ID

23682586

29 August 2017

Chi Chiu Leung

series ordinal

4

1 reference

29 August 2017

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

18

1 reference

29 August 2017

6

1 reference

29 August 2017

912-922

1 reference

HIV infection-associated tuberculosis: the epidemiology and the response

29 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Epidemiology of tuberculosis and HIV: recent advances in understanding and responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

A cross-sectional study of HIV and tuberculosis coinfection cases in mainland China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The changing pattern of tuberculosis and HIV co-infection in immigrants and Spaniards in the last 20 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Immunogenetics of HIV and HIV associated tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Increasing incidence of tuberculosis in a prison inmate population. Association with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Prevalence of smear positive pulmonary tuberculosis among prisoners in North Gondar Zone Prison, northwest Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Tuberculosis in a prison population in Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

HIV infection and multidrug-resistant tuberculosis: the perfect storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Timing of initiation of antiretroviral drugs during tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Pharmacokinetic interactions between etravirine and non-antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Treatment of latent infection with Mycobacterium tuberculosis: update 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Treatment of latent tuberculosis infection in HIV infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Isoniazid preventive therapy and risk for resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

New regimens to prevent tuberculosis in adults with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Mining and risk of tuberculosis in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

Clinical management of tuberculosis and HIV-1 co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12120

21 January 2018

Identifiers

DOI

10.1111/RESP.12120

1 reference

29 August 2017

1 reference

PubMed ID

23682586